Amendments to the Claims

1. (Currently Amended) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof;



(I)

wherein ;

R_1 is (c) wherein;

(c) is the group -(L_1)-R_{11}; where, -(L_1)- is ~~a divalent linking group~~an alkylene chain of 1 to 8 carbon atoms and where R_{11} is $-(CH_2)_m-R_{12}$; wherein m is an integer from 0 to 2; and R_{12} is the group represented by the formula:



where n is an integer from 0 to 2 and p is an integer from 0 to 2; and R_{13} is selected from C_1 to C_8 alkyl;

R_2 is hydrogen, or C1-C4 alkyl;

R_3 is -(L_3)- Z, where -(L_3)- is a ~~divalent linker group selected from a~~ bond ~~or:~~



[[-CH2-]]

and Z is a group represented by the formulae,



wherein, X is oxygen ~~or sulfur~~; and R_a is selected from hydrogen, C_1-C_8 alkyl, aryl, C_1-C_8 alkaryl, C_1-C_8 alkoxy, aralkyl and -CN;

R_4 is the group, -(L_h)-(hydroxyfunctional amide); wherein -(L_h)-, is ~~an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8~~represented by the formula



Q_2 is O;

R^{40} is independently selected from hydrogen and C_1-C_8 alkyl;

(Hydroxyfunctional amide) is the group



wherein R^{4a} is OH;

R^{4b} is selected from the group consisting of H and C_1-C_8 alkyl;

R_5 is ~~selected from~~ hydrogen~~, a non-interfering substituent, or the group, (L_a)-(acidic group), wherein (L_a), is an acid linker having an acid linker length of 1 to 8~~; and

R_6 and R_7 are independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl.

2. (Cancelled)

3. (Cancelled)

4. (Currently Amended) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(Lh)-, for R_4 is a divalent group selected from,



or



~~where R_{40}, R_{41}, R_{42}, and R_{43} are each independently selected from hydrogen, C_1-C_8-alkyl~~.

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Currently Amended) The compound of claim 1 wherein R4 is the group, ~~-(L_e)-(hydroxyfunctional-(L_h)-~~(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and R^{4a} is independently selected from the group consisting of OH~~, (C_1-C_6)alkoxy, (C_7-C_{14})alkaryloxy, (C_2-C_8)alkenyloxy, (C_7-C_{14}) aralkyloxy, (C_7-C_{14})aralkenyloxy and aryloxy~~; and

wherein R^{4b} is (C_1-C_6)alkyl.

~~wherein R^{4b} is independently selected from the group consisting of H, (C_1-C_6)alkyl, arylalkyl, heteroaryl and aryl.~~

19. (Cancelled)

20. (Previously Presented) A compound selected from the group of:

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(methyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(2-propenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(2-propyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(tert-butyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-[2-(methyl)propyloxy]acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(cyclohexyl)-*N*-(hydroxy)acetamide; and

2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide.

21. (Cancelled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Cancelled)

24. (Cancelled)

25. (Previously Presented) A pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. (Cancelled)

27. (Cancelled)